Biotechnological companies using AI
Tempus AI, Inc. (NASDAQ: TEM), an AI precision medicine company, reported 33% organic growth in Q4 2025, with Diagnostics revenue expanding due to higher test average selling prices. The company projects 2026 revenues of approximately $1.59 billion, representing 25% year--over--year growth. Despite these results, the stock declined nearly 7% in mid--day trading on February 25, 2026, due to limited guidance above consensus analyst expectations.